Timothy Lu is the chief executive officer and co-founder of Senti Biosciences, a biotech company developing next-generation cell and gene therapies enabled by synthetic biology. He started his career as a faculty member at MIT in 2010 in the department of electrical engineering and computer science and the department of biological engineering. Tim graduated with his S.B. and Master’s degree in engineering from MIT, and his doctor of medicine / doctor of philosophy from the Harvard-MIT Health Sciences and Technology Program.
Tim’s research focuses on using systems biology and synthetic biology to understand natural biological networks and design synthetic ones for therapeutic applications. He is a recipient of the ACS Synthetic Biology Young Investigator Award, the Biochemical Engineering Journal Young Investigator Award, the National Institutes of Health (NIH) New Innovator Award, the Presidential Early Career Award for Scientists and Engineers and the Ellison Medical Foundation New Scholar in Aging Award, among others.